Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Oligodendroglioma: early-phase trial registry
7 of 15 indexed Oligodendroglioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 7 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Oligodendroglioma: 15 US clinical trials tracked, 7 recruiting.
Oligodendroglioma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Jennie Taylor, running 1 of these trials.
Enrollment posture brief
Registry condition oligodendroglioma
OPEN 7 | RECR 47% | LATE 1 | EARLY 11 | RANK #1140 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Autism (47% recruiting · 105 trials)
Oligodendroglioma lists 7 open slots (47% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Oligodendroglioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Oligodendroglioma recruits in line with its size-band peers.
7 of 15 indexed trials (46.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Oligodendroglioma trials is spread across many organizations.
Jennie Taylor accounts for 1 of 15 trials (6.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Oligodendroglioma trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Oligodendroglioma research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Nuvation Bio
NCT05303519
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
Dartmouth-Hitchcock Medical Center
NCT06930846
FearLess in NeuroOncology
Virginia Commonwealth University
NCT06989086
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT04541082
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Stephen Bagley, MD, MSCE
NCT05345002
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
NCT04623931
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
NCT05956821
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
NCT03180502
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Dana-Farber Cancer Institute
NCT03152318
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Institut de Recherches Internationales Servier
NCT05484622
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato
NCT05561374
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
University of Florida
NCT07031765
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
NCT01609790
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Wake Forest University Health Sciences
NCT02747407
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
Jennie Taylor
NCT02549833
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Oligodendroglioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Oligodendroglioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Oligodendroglioma page
15 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Oligodendroglioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jennie Taylor sponsors the most Oligodendroglioma trials on record, review their full trial history before evaluating a specific study. See Jennie Taylor's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Oligodendroglioma condition card totals 15 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.